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Summary
We report that human secretory breast carcinoma (SBC), a rare subtype of infiltrating ductal carcinoma, expresses the
ETV6-NTRK3 gene fusion previously cloned in pediatric mesenchymal cancers. This gene fusion encodes a chimeric
tyrosine kinase with potent transforming activity in fibroblasts. ETV6-NTRK3 expression was confirmed in 12 (92%) of 13
SBC cases, but not in other ductal carcinomas. Retroviral transfer of ETV6-NTRK3 (EN) into murine mammary epithelial
cells resulted in transformed cells that readily formed tumors in nude mice. Phenotypically, tumors produced glands and
expressed epithelial antigens, confirming that EN transformation is compatible with epithelial differentiation. This represents
a recurrent chromosomal rearrangement and expression of a dominantly acting oncogene as a primary event in human
breast carcinoma.
Introduction t(12;15)(p13;q25) associated with congenital fibrosarcoma
(CFS), a pediatric spindle cell malignancy of the soft tissues
Among human solid tumors, sporadic breast cancer is similar (Knezevich et al., 1998b). This rearrangement generates a gene
to the vast majority of epithelial malignancies in that it appears to fusion encoding the sterile motif (SAM) dimerization domain of
have a complex genetic etiology. The numerous rearrangements the ETV6 (TEL) transcription factor linked to the protein tyrosine
and gains and losses of chromosomal material observed cyto- kinase (PTK) domain of the neurotrophin-3 receptor NTRK3
gentically in tumor cells have precluded the discovery of primary (TRKC) (Knezevich et al., 1998b). The resulting ETV6-NTRK3
genetic lesions underlying breast cancer development (Dickson (EN) protein functions as a chimeric PTK with potent trans-
and Lippman, 2001). This is in contrast to bone and soft tissue forming activity (Wai et al., 2000; Liu et al., 2000). EN expression
sarcomas of children and young adults, which often show recur- leads to constitutive activation of two major effector pathways
rent chromosomal translocations leading to expression of gene of wild-type NTRK3, namely the Ras-MAP kinase (MAPK) mito-
fusions thought to be causally related to oncogenesis (Ladanyi genic pathway and the phosphatidyl inositol-3-kinase (PI3K)-
and Bridge, 2000). However, the occurrence of such transloca- AKT pathway mediating cell survival, and both are required for
tions as the sole cytogenetic alteration in epithelial tumors is EN transformation (Wai et al., 2000; Tognon et al., 2001). ETV6-
extremely rare. NTRK3 fusion transcripts have also been identified in a related
pediatric tumor, cellular mesoblastic nephroma (CMN) (Kneze-We previously cloned the translocation breakpoints of the
S I G N I F I C A N C E
Mechanisms of oncogenesis in sporadic breast cancer remain for the most part obscure. This is due in large part to the marked
cytogenetic complexity seen in most breast cancers, precluding investigators from readily identifying primary genetic events that
may be causative in breast cell transformation. Our findings, although limited to a rare but distinct subset of breast cancers, describe
a potentially causative genetic event in sporadic human breast carcinoma and establish ETV6-NTRK3 as a dominantly acting
oncogene in this disease. Therefore, the transformation of breast epithelial cells by the ETV6-NTRK3 oncoprotein may provide an
extremely useful model to study pathways underlying the initiation and progression of human breast cancer, and how those pathways
may be targeted therapeutically.
CANCER CELL : NOVEMBER 2002 · VOL. 2 · COPYRIGHT  2002 CELL PRESS 367
A R T I C L E
Figure 1. Histologic and cytogenetic findings in
the index secretory breast carcinoma case
A: Histology of index secretory breast carcinoma
(SBC) case demonstrating well-differentiated
but invasive glands containing eosinophilic se-
cretions.
B: Partial karyogram demonstrating the
t(12;15)(p13;q25) in secretory breast carcinoma
occurring in a 6-year-old female. Arrowheads
show breakpoints at derivative 12p13 and deriv-
ative 15q25.
C: Dual color FISH using ETV6 exon 1-containing
cosmid 179A6 (green) and ETV6 exon 8-con-
taining cosmid 148B6 (Knezevich et al., 1998b).
Arrows show separate signals indicating disrup-
tion of the ETV6 gene.
vich et al., 1998a; Rubin et al., 1998), and in a case report an infiltrating pattern of neoplastic epithelial cells forming well-
of adult acute myeloid leukemia (AML) (Eguchi et al., 1999). differentiated glandular lumens filled with eosinophilic PAS-pos-
Therefore, this gene fusion is unique in being expressed in both itive secretions (Rosen and Cranor, 1991). Karyotypic analysis
mesenchymal and hematopoietic lineages. revealed a t(12;15)(p12;q26.1) translocation as the only cytoge-
The possibility that ETV6-NTRK3 fusion transcripts are ex- netic abnormality in tumor cells (Figure 1B). This translocation
pressed in human breast cancer was suggested to us by cytoge- was not present constitutionally. The karyotype prompted us
netic analysis of an invasive breast adenocarcinoma diagnosed to perform fluorescence in situ hybridization (FISH) and reverse
in a 6-year-old female. This revealed a nonconstitutional transcriptase PCR (RT-PCR) on frozen tumor tissue from the
t(12;15)(p12;q26.1) as the only karyotypic abnormality in tumor case to screen for the ETV6-NTRK3 gene fusion. As shown in
cells. The histopathologic features of the tumor were those of Figure 1C, dual color FISH using cosmid probes from exon 1
a secretory breast carcinoma (SBC). This is a rare but distinct and exon 8 of ETV6 demonstrated rearrangement of the ETV6
subtype of infiltrating ductal carcinoma (IDC) that was originally locus. Moreover, RT-PCR revealed an identical 731 bp fusion
described in children and adolescents, but is now known to transcript as previously described for CFS and CMN (Knezevich
occur with equal incidence in adults (Page et al., 1987; Oberman, et al., 1998a, 1998b) (Figure 2A). This was confirmed by se-
1980). Although recurrences and nodal metastases can occur quencing of the amplification products, which demonstrated
in SBC, the prognosis was initially thought to be excellent com- the identical fusion point between ETV6 nucleotide 1033 and
pared to typical IDC, with up to a 100% five-year survival rate NTRK3 nucleotide 1601 as previously shown for sarcoma-asso-
(Tavassoli and Norris, 1980; Rosen and Cranor, 1991). However, ciated fusions (Knezevich et al., 1998b) (Figure 2B). This differs
more recent studies have suggested that the favorable outcome from the ETV6-NTRK3 gene fusion reported in a case of acute
is age-related, and that in older patients the prognosis is similar myeloid leukemia, in which ETV6 exon 5 was not present in the
to IDC (Maitra et al., 1999). In this report we demonstrate that
fusion (Eguchi et al., 1999). Furthermore, we generated RT-PCR
SBC is characterized by expression of the ETV6-NTRK3 gene
products from the SBC case using the TEL 114 primer (locatedfusion, and that ETV6-NTRK3 can transform mammary epithelial
5 of the ETV6 SAM sequence) in combination with the TRKC2cells. This fusion oncoprotein is therefore causally related to
primer located within the NTRK3 PTK sequence (Knezevich ettransformation across all germ layers, a finding which has poten-
al., 1998b), as well as using the TEL 541 primer from ETV6 exontial implications for how we view the specificity of chromosomal
5 (Knezevich et al., 1998b) in conjunction with the Trk1 primertranslocations in human tumors.
(Wai et al., 2000) from exon 18 of NTRK3 located 3 of the PTK
sequence (Ichaso et al., 1998) (see Figure 2B). These productsResults
were confirmed to contain identical sequences to those of CFS
fusion transcripts and demonstrated that the entire SAM andIdentification of the t(12;15) translocation and ETV6-NTRK3
PTK domains were included in the SBC transcripts (see Gen-gene fusion in a human secretory breast carcinoma case
Bank accession #AF041811). We also found that, similar to CFSThe index case was a 6-year-old female who presented with a
gene fusions, SBC transcripts did not contain NTRK3 exon 16,unilateral breast mass. Pathology revealed an invasive breast
which encodes a 42 bp insert within the PTK sequences (Ichasoadenocarcinoma with the histopathologic features of a secretory
breast carcinoma (SBC) (Figure 1A). SBC is characterized by et al., 1998). The presence of these naturally occurring inserts
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Figure 2. Characterization of the ETV6-NTRK3
gene fusion and encoded protein in the index
secretory breast carcinoma case
A: Reverse transcriptase-PCR of ETV6-NTRK3 fu-
sion transcripts using total RNA isolated from fro-
zen tumor tissue of the index secretory breast
carcinoma case (SBC) and a congenital fibro-
sarcoma control (CFS), but not from 10 infiltrating
ductal carcinoma cases (lanes 1–10). M, mark-
ers; –C, negative control.
B: Schematic diagram showing the structure of
the ETV6-NTRK3 chimeric cDNA in secretory
breast carcinoma. Exons 1–5 of ETV6 (blue boxes)
are fused in frame with exons 13–15 and 17–18
of NTRK3 (red boxes). The lighter shade of blue
indicates the region encoding the ETV6 sterile-
-motif (SAM) domain, while the lighter shade
of red indicates the region encoding the NTRK3
protein tyrosine kinase (PTK) domain. Numbers
above the exons indicate the last nucleotide of
each exon. The fusion point is between ETV6 nu-
cleotide 1033 and NTRK3 nucleotide 1601 (indi-
cated by the vertical arrow) which is identical
to that observed in congenital fibrosarcoma. The
positions of the TEL114 and TEL541 forward prim-
ers and the TRKC2 and TRK1 reverse primers used
to characterize ETV6-NTRK3 fusion transcripts are
shown under the exons (see text). An expanded
view of the ETV6-NTRK3 breakpoint sequence in
the index secretory breast carcinoma case is shown below the cDNA schematic. This was derived by sequencing of RT-PCR products using primers TEL-
541 and TRKC2. Identical sequences were observed in multiple clones from three separate experiments. The vertical arrow shows the fusion point.
C: Immunoprecipitation of the ETV6-NTRK3 protein using -NTRK3 antibodies followed by Western analysis with -phosphotyrosine antibodies. The left panel
demonstrates the characteristic tyrosine phosphorylated 68/73 kDa ETV6-NTRK3 doublet in the index secretory breast carcinoma case (SBC), two CFS
primary tumors (CFS1 and 2), and in NIH3T3 cells expressing ETV6-NTRK3 (3T3-EN), but not in the NIH3T3 vector control (3T3-Vec). The right panel demonstrates
the doublet only in the 3T3-EN control cells but not in lysates from three invasive breast carcinoma cases (IBC1-3) nor in 3T3-Vec cells. The 68/73 kDa ETV6-
NTRK3 doublet is indicated by the arrow.
is known to decrease NTRK3 PTK activity (reviewed in Barbacid, fully cloned PCR products from four of these additional positive
cases, and sequence analysis confirmed that all four had1994).
breakpoint sequences that were identical to each other and toTo show that the ETV6-NTRK3 protein was expressed in
a control CFS case, with fusion points between ETV6 nucleotidetumor tissue, we performed immunoprecipitation of whole cell
1033 and NTRK3 nucleotide 1601 (data not shown). To testlysates from the primary tumor using -NTRK3 antibodies fol-
whether this gene fusion is specific for SBC, we also screenedlowed by Western blotting with -phosphotyrosine antibodies
a series of banked frozen specimens from 50 cases of typicalas described (Wai et al., 2000). This revealed expression of the
IDC as well as FFPE blocks from 5 of these cases (cases 14–18characteristic tyrosine phosphorylated 68/73 kDa doublet of EN
of Table 1). All were fusion negative except for one case (case(Figure 2C, left panel), which was confirmed by reprobing of the
14 of Table 1), in which, unexpectedly, fusion transcripts couldblot with -NTRK3 and -ETV6 antibodies (data not shown).
be demonstrated in both the frozen specimen and in the corre-The tyrosine phosphorylated doublet was not detected in three
sponding FFPE block from this case (Figure 3A).control primary invasive ductal carcinomas that were negative
To confirm these findings, we next performed dual colorfor the ETV6-NTRK3 gene fusion by RT-PCR (Figure 2C, right
FISH analysis on nuclei isolated from FFPE blocks using yeastpanel).
artificial chromosomes (YACs) containing the ETV6 and NTRK3
loci, respectively. Nine of the 13 SBC cases (including the index
Analysis of ETV6-NTRK3 transcript expression case) had adequately preserved nuclei for FISH analysis, as did
in a series of secretory breast carcinomas each of the five IDC FFBE blocks. The nine SBC cases with
To test whether ETV6-NTRK3 expression represents a general- evaluable nuclei were all positive by FISH for the ETV6-NTRK3
ized finding in SBC, we accrued 12 additional breast cancer gene fusion (see Figure 3B and Table 1). Moreover, the IDC
cases in which SBC was the predominant or only histologic case that was positive by RT-PCR (case 13) was also positive
component (for clinical features see Table 1). The diagnoses by FISH while the other FFBE blocks were negative (Table 1).
were independently confirmed by three of the authors (DH, CP, Further review of pathologic material from case 14 revealed
and PHBS). Only formalin-fixed paraffin-embedded (FFPE) tu- several areas of well-differentiated glands containing eosino-
mor blocks were available for each case. We therefore used an philic secretions (data not shown). Therefore this case may have
RT-PCR assay adapted to FFPE tissue which detects a 110 bp originated as an SBC, but underwent further clonal evolution to
fragment (Bourgeois et al., 2000). We detected ETV6-NTRK3 assume a less differentiated phenotype. These findings strongly
fusion transcripts in 11 of the 12 cases, as well as in FFPE indicate that the ETV6-NTRK3 gene fusion is a nonrandom re-
arrangement in SBC.blocks from the index case (Figure 3A and Table 1). We success-
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Table 1. Breast carcinomas tested for t(12;15)-associated ETV6-NTRK3 fusion transcripts by reverse transcriptase-PCR (RT-PCR) and fluorescence in situ
hybridization (FISH)
Case Sex Age at Dx (yrs) Diagnosis RT-PCR FISH
1 f 6 secretory carcinoma pos pos
2 f 19 secretory carcinoma pos NI
3 m 75 gynecomastia with secretory neg NI
carcinoma
4 f 57 secretory carcinoma pos NI
5 f 49 secretory carcinoma pos NI
6 f 59 secretory carcinoma pos pos
7 f 39 mixed ductal and secretory pos pos
carcinoma
8 f 64 secretory carcinoma pos pos
9 f 76 secretory carcinoma pos pos
10 f 63 secretory carcinoma pos pos
11 f 63 secretory carcinoma pos pos
12 f 62 secretory carcinoma pos pos
13 f 42 secretory carcinoma pos pos
14 f 63 ductal carcinoma pos pos
15 m 16 ductal carcinoma neg neg
16 f 84 ductal carcinoma neg neg
17 f 59 ductal carcinoma neg neg
18 f 56 ductal carcinoma neg neg
Abbreviations: Dx, diagnosis; f, female; m, male; pos, positive; neg, negative; NI, not informative.
ETV6-NTRK3 transforms Eph4 and Scg6 breast and Scg6 cells. These are immortalized nontransformed epithe-
epithelial cells lial cell lines derived from normal mouse mammary epithelium
To demonstrate that ETV6-NTRK3 has transformation activity (Roskelley et al., 2000; Somasiri et al., 2001). We chose these
in breast epithelial cells, we used previously described retroviral lines because they represent opposite ends of the spectrum
gene transfer methods (Wai et al., 2000) to express EN con- of mammary epithelial differentiation, with Scg6 cells showing
structs versus vector alone in clonal populations of murine Eph4 stable myoepithelial (more mesenchymal) features and Eph4
cells showing a stable epithelial phenotype in culture. After infec-
tion with ETV6-NTRK3 constructs, both cell lines were found
to express ETV6-NTRK3 at levels that were equivalent to those
observed in EN-transformed NIH3T3 cells (Figure 4A). Morphol-
ogy of Eph4-EN and Scg6-EN cells in monolayer cultures sug-
gested a transformed phenotype compared with vector alone
cells (data not shown). To more rigorously demonstrate that EN
had transforming ability in these cells, EN-expressing and vector
alone cells were simultaneously injected subcutaneously into
the right or left flanks, respectively, of nude mice. Tumor forma-
tion was then monitored for up to six weeks in comparison with
EN-expressing NIH3T3 cells. Eph4 and Scg6 cells containing
vector alone showed no tumor formation whatsoever (Figure
4B). In contrast, both cell lines formed obvious tumors when
engineered to express EN. All Eph4-EN and Scg6-EN injection
sites showed tumor formation, although tumor sizes were vari-
able (Figure 4B). Interestingly, tumors derived from the two
breast epithelial cell lines consistently grew more slowly com-
pared with EN-expressing NIH3T3 cells, although they eventu-
ally attained the same sizes and weights (Figure 4C). These
findings confirm that EN has transformation activity in breast
Figure 3. Detection of the ETV6-NTRK3 gene fusion in a series of secretory epithelial cells, and strongly implicate EN as being causally
breast carcinomas
related to oncogenesis in human SBC.
A: Reverse transcriptase-PCR of ETV6-NTRK3 fusion transcripts (arrow) using
total RNA isolated from formalin-fixed paraffin-embedded tumor blocks of
Pathology of tumors derived from ETV6-NTRK3the index secretory breast carcinoma case (SBC) as well as in cases 2, 3,
and 14 from Table 1 (lanes 1–3, respectively), but not in case 15 (lane 4). expressing Eph4 and Scp6 cells
CFS, congenital fibrosarcoma control. We next assessed histopathologic sections from Scg6 and Eph4
B: Dual-colored FISH of CFS case 2 metaphase using the 12p13 breakpoint- derived tumors expressing EN. All Scg6-EN tumors had a mes-
spanning YAC, 817_H_1 (green), and the 15q25 breakpoint-spanning YAC,
enchymal phenotype that was indistinguishable from the fibro-802_B_4 (red) (Knezevich et al., 1998b). Representative fusion signals are
shown by the arrows. sarcoma appearance of EN-expressing NIH3T3 tumors (see Fig-
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Figure 4. Transformation of murine breast epithe-
lial cells by the ETV6-NTRK3 chimeric oncoprotein
A: Expression of ETV6-NTRK3 in Eph4 and Scg6
breast epithelial cells. NIH3T3 fibroblasts and
Eph4 or Scg6 breast epithelial cells were infected
with retroviruses containing control vector alone
(C) or ETV6-NTRK3 (EN) and were grown to near
confluence. Whole cell lysates (500 g) were
then collected and subjected to immunopre-
cipitation with -NTRK3 antibodies. Immunopre-
cipitates were separated by SDS-PAGE and
subjected to 4G10 anti-phosphotyrosine immu-
noblotting. A tyrosine phosphorylated doublet at
68 and 73 kDa is seen in lysates from EN infected
cells.
B: Tumor formation after injection of Eph4 and
Scg6 cells expressing ETV6-NTRK3. Vector control
Eph4 or Scg6 cells were injected subcutaneously
into the left flanks of nude mice, while Eph4 or
Scg6 cells expressing ETV6-NTRK3 were simulta-
neously injected into the right flanks of the same
mice. As indicated by the arrowheads, tumors
formed only on the right flanks of these mice.
C: Growth rates for nude mouse tumors after sub-
cutaneous cell injections. There was no tumor
growth for NIH3T3, Eph4, and Scg6 control cells
expressing vector alone. In contrast, the same
cell lines expressing ETV6-NTRK3 (EN-NIH3T3,
EN-Eph4, and EN-Scg6, respectively) all formed
identifiable tumors, which were monitored for
size over a six week period. The growth curves
shown are representative results for the largest
tumors observed for each cell line.
ures 5A and 5B). There was no gland formation or other evidence tumor cells maintained the ability to undergo epithelial differenti-
ation, which is consistent with our premise that EN is a trans-of epithelial differentiation. As shown in Figures 5D and 5E,
NIH3T3-EN and Scg6-EN cells were negative by immunohisto- forming oncoprotein not only in mesenchymal cells but also in
breast epithelial cells.chemistry for cytokeratin or other epithelial markers, but were
positive for the mesenchymal intermediate filament, vimentin
(Figures 5G and 5H). In contrast, Eph4-EN derived tumors Discussion
showed obvious gland formation and sheets of epithelioid cells
(Figure 5C). Gland cells were strongly positive for cytokeratin In this report we show that human secretory breast carcinoma
is characterized by expression of the t(12;15)-associated ETV6-(Figure 5F) and epithelial membrane antigen (data not shown)
but negative for vimentin (Figure 5I). Adjacent to the epithelial NTRK3 gene fusion. Moreover, we demonstrate that the ETV6-
NTRK3 chimeric product can transform normal mouse mam-clusters were bands of vimentin-positive, cytokeratin-negative
cells with a similar mesenchymal appearance as the Scg6-EN mary epithelial cells, strongly implicating this oncoprotein as
being causally related to the development of SBC. SBC there-tumors. There was an approximately equal contribution of the
epithelial and mesenchymal neoplastic cells to the Eph4-EN fore joins a very select group of epithelial malignancies, namely
subtypes of thyroid carcinomas (Pierotti, 2001), renal carcino-tumors. Immunohistochemical staining of sections using
-NTRK3 antibodies demonstrated EN expression in the mas (Cooper and Shipley, 2002), and aggressive sinonasal car-
cinoma (French et al., 2001), for which recurrent gene fusionsNIH3T3-EN and Scg6-EN cells (Figure 5J and 5K), and in both
the glandular and mesenchymal elements of the Eph4-EN de- have been described. ETV6-NTRK3 is unique among these gene
fusions in that it is expressed in multiple tumor types includingrived tumors (Figure 5L). These data show that EN-expressing
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Figure 5. Histology of tumors formed after injection of ETV6-NTRK3 expressing NIH3T3 cells (EN-NIH3T3), Scg6 cells (EN-Scg6), or Eph4 cells (EN-Eph4) into nude
mice
No tumors formed after injection of vector alone control cells. A–C: Photomicrographs of hematoxylin & eosin stained tumor sections. Formation of glandular
and papillary epithelial structures (e.g., arrowhead in C) was observed only in EN-Eph4 tumors. D–L: Immunohistochemical staining of sections from EN-NIH3T3,
EN-Scg6, or EN-Eph4 tumors using antibodies directed against the epithelial intermediate filament cytokeratin (D–F), the mesenchymal intermediate filament
vimentin (G–I), and NTRK3 as a marker of ETV6-NTRK3 expression (J and K). Arrowheads in the EN-Eph4 panels indicate positive immunostaining of glandular
structures for cytokeratin (F), lack of immunostaining of glandular structures for vimentin (I), and positive immunostaining in both mesenchymal and glandular
elements for ETV6-NTRK3 (L).
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those derived from mesenchymal (Knezevich et al., 1998a, promoter of a given chimeric gene is not active in a particular
cell type, then the product of that gene will not be expressed.1998b; Rubin et al., 1998), hematopoietic (Eguchi et al., 1999),
and now epithelial cells. Similarly, if a chimeric oncoprotein is generally not tolerated in
cells, e.g., if it induces apoptosis, then it will only be expressedThe identification of an ETV6-NTRK3 gene fusion in SBC
describes a recurrent chromosomal rearrangement and expres- in cell types with mechanisms for circumventing oncogene-
induced apoptotic pathways. Evidence for the latter comes fromsion of a dominantly acting oncogene as a primary event in
breast carcinoma. The chromosomal instability observed in the recent studies of the Ewing tumor-associated EWS-FLI1 chime-
ric transcription factor. Expression in primary human fibroblastsvast majority of epithelial malignancies, leading to numerous
rearrangements, gains, and losses of chromosomal material activated a p53-dependent growth arrest pathway and down-
regulated numerous cell cycle progression related genes (Less-(Dickson and Lippman, 2001), has precluded the discovery of
primary genetic events underlying the development of epithelial nick et al., 2002). This suggests that cells transformed by EWS-
FLI1 must coactivate pathways that specifically abrogatetumors. If expression of ETV6-NTRK3 is indeed a causal event
in secretory breast carcinoma, then transformation of breast EWS-FLI1-induced growth arrest in order for mitogenesis to
occur and for tumors to form. The second explanation for tumorepithelial cells by the EN oncoprotein may provide an extremely
useful model to study pathways leading both to the initiation specificity of fusion genes proposes that the chimeric oncopro-
tein itself can induce differentiation, giving rise to the observedand progression of breast cancer. In fact, there are several
parallels between the signaling alterations described for EN phenotype. Many gene fusions in hematopoietic malignancies
and sarcomas encode chimeric transcription factors (Sorensenfibroblast transformation and those observed in breast cancer.
We previously reported that EN is a potent transforming protein and Triche, 1996). Therefore these proteins may transcriptionally
activate specific differentiation programs. EWS-FLI1 expressionin NIH3T3 cells and that this activity requires a functional NTRK3
PTK domain (Wai et al., 2000). Moreover, EN transformation in NIH3T3 cells was associated with a small round cell morphol-
ogy and limited neural differentiation in nude mouse tumorsleads to marked induction of cyclin D1 and is dependent on two
major effector pathways of wild-type NTRK3, the Ras-MAPK (Teitell et al., 1999), and a myogenic transcription program was
induced in NIH3T3 cells expressing the alveolar rhabdomyosar-pathway and the PI3K-AKT pathway (Wai et al., 2000; Tognon
et al., 2001). Amplification and overexpression of the cyclin D1 coma-associated PAX3-FKHR protein (Khan et al., 1999).
We favor the view that some chimeric oncoproteins such(CCND1) gene is a well-known progression-related alteration in
breast cancer (Buckley et al., 1993; Wang et al., 1994; Sicinski as EN may activate transformation pathways that function inde-
pendently of lineage constraints and do not directly affect differ-et al., 1995), being present in approximately one-third of invasive
cases (Zukerberg et al., 1995). Moreover, the Ras-MAPK and entiation programs. These oncoproteins may modulate com-
mon signal transduction cascades present in diverse cell typesPI3K-AKT pathways are receiving increasing attention as poten-
tial therapeutic targets in breast cancer (reviewed in Malaney that potentiate downstream proliferative effects such as transit
through the cell cycle. In such a scenario it may be the abilityand Daly, 2001, and Mills et al., 2001, respectively). Another
pathway suspected to play a key growth regulatory role in breast of the cell to tolerate the potentially toxic consequences of
fusion protein expression, such as by activating complementarycancer is the insulin-like growth factor 1 receptor (IGFRI) cas-
cade (reviewed in Zhang and Yee, 2000). Interestingly, we re- cell survival pathways, which determines whether or not tumor
formation occurs. In this context, the observed morphology ofcently found that expression of functional IGFRI is essential for
EN-mediated transformation, as EN fails to transform IGFRI neoplastic cells results from developmental programs already
present in tumor precursor cells. Therefore the perceived speci-null fibroblasts (Morrison et al., 2002). EN transformation may
provide a unique model to study how these and other pathways ficity of gene fusions may be more a function of the available
complement of secondary pathways or the tendency for re-contribute to breast oncogenesis. It will also be important to
determine whether activation of the NTRK receptor PTK family quired additional mutations to occur than of the intrinsic differ-
entiation program available in the precursor cell.by alternative mechanisms is a more general phenomenon in
human breast cancer. In fact, recent reports document NTRK
Experimental proceduresexpression in malignant breast epithelial cells (Descamps et al.,
1998, 2001b, 2001a).
Patient information
Tumors derived from EN-expressing Eph4 cells showed epi- The clinical features of the 13 SBC cases assessed in this study are listed
thelial differentiation with cytokeratin- and EMA-positive gland in Table 1. The cases were accrued from Pathology departments at four of
formation. Therefore not only is EN capable of transforming the authors’ institutions (Children’s and Women’s Health Centre of British
Columbia, Hospital for Sick Children, Instituto de Patologia e Imunologiacells with epithelial developmental potential, but it does not
Molecular da Universidade do Porto, and Gerhard-Domagk-Institute of Pa-block epithelial differentiation, in keeping with the well-differenti-
thology, Westfaelische-Wilhelms University) and from Burnaby General Hos-ated histology of human SBC. However, the fact that EN expres-
pital, Burnaby, Canada. The age range was 6 to 76 years, and there was
sion is associated with tumors derived from multiple lineages a 12:1 female to male ratio. Assessment of the pathologic records and
calls into question the concept that gene fusions are specific independent review of slides from each case confirmed the secretory compo-
for given tumor types (Rabbitts, 1994). Two possible mecha- nent as being the predominant or exclusive morphology present in the tu-
mors, other than in cases 3 and 7. In case 3 the secretory carcinoma compo-nisms have been proposed to explain the strong association
nent was present within a background of gynecomastia, while in case 7 thebetween acquired chromosomal translocations and specific tu-
secretory component was admixed approximately equally with non-SBCmor types that has been documented in hematopoietic malig-
infiltrating ductal carcinoma. All blocks used for molecular analysis werenancies and sarcomas (Barr, 1998). The first proposes that the
screened for the presence of at least 50% viable tumor tissue. Table 1 also
lineage of a cell imposes constraints on whether or not a particu- includes clinical information on five infiltrating ductal carcinoma cases from
lar chimeric oncoprotein will be expressed or have pathologic which formalin-fixed paraffin-embedded blocks were used as controls for
molecular analysis.consequences in that cell type. For example, if the functional
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Cytogenetic analysis from Dr. Rob Kay (Terry Fox Laboratory, Vancouver, Canada) and grown in
DMEM containing 10% fetal calf serum (FCS; GIBCO-BRL). The mouseTumor tissue for cytogenetic analysis was collected from the index case at
the time of surgery. Cytogenetic techniques used for chromosome analysis mammary epithelial cells lines, Scg6 and Eph4, were obtained from Dr. Calvin
Roskelley (Dept. of Anatomy, University of British Columbia, Vancouver, BC,have been described previously (Sandberg and Bridge, 1994). The samples
were mechanically and enzymatically disaggregated and cultured in RPMI Canada) and maintained in DMEM/F12 (Sigma) supplemented with 5% FBS
(Hyclone), insulin (5 g/ml; Sigma), and gentamicin (50 g/ml, GIBCO-BRL).1640 medium supplemented with 20% fetal calf serum, 1% penicillin/strep-
tomycin, and 1% L-glutamine for several days. Six hours before harvesting,
cells were exposed to Colcemid (0.02 g/ml). After a brief incubation in Generation of retrovirally transduced cell lines
hypotonic solution, the preparations were fixed with methanol-glacial acetic Retroviral vector plasmid DNAs (MSCV-puromycin vector or MSCV puromy-
acid (3:1). Metaphase cells were banded with Wright stain or with Giemsa cin ETV6-NTRK3 [Wai et al., 2000]) were transfected into the BOSC23 eco-
trypsin. A minimum of 20 metaphases were analyzed for each specimen. tropic retroviral packaging cell line using calcium phosphate precipitation
Karyotypes were in accordance with the International System for Human as described (Pear et al., 1993). Supplemental Gag/Pol (pGP1) and Env
Cytogenetic Nomenclature (1995). plasmids were used during the transfection procedure to increase viral titres.
Retrovirus-containing supernatants were collected 48 hr after transfection
and used to infect NIH3T3, Scg6, and Eph4 cells. Infected cells were selectedRT-PCR analysis of breast tumor specimens
for using 1.5 g/ml puromyocin (Sigma) for 48 hr. Protein expression wasReverse transcriptase-polymerase chain reaction (RT-PCR) was used to
determined by Western blotting as described (Wai et al., 2000).screen for ETV6-NTRK3 fusion transcripts in frozen tissue samples from the
index case and an additional 50 control cases of infiltrating ductal carcinoma
Immunoprecipitation studiesusing previously described methods (Knezevich et al., 1998b). Total RNA
Lysates were prepared from scrolls of frozen tumor samples embedded inwas used as starting material and was isolated using standard procedures.
OCT using a RIPA lysis buffer consisting of 20 mM Tris pH 7.4; 120 mM NaCl,The TEL541 forward primer (5-CCTCCCACCATTGAACTGTT-3) and the
1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 10% glycerol, 5TRKC2 reverse primer (5-CCGCACACTCCATAGAACTTGAC-3) were used
mM EDTA, 50 mM NaF, 0.5 mM Na3VO4, plus freshly added protease inhibi-for PCR. Amplified products were visualized by electrophoresis using 2%
tors (Leupeptin [10 g/ml], Apoprotinin [10 g/ml], and PMSF [250 M]).agarose gels stained with ethidium bromide. ETV6-NTRK3 amplification
Lysates prepared from cell lines were prepared as described previouslyproducts were confirmed by blotting the PCR fragments onto Hybond-N
(Tognon et al., 2001). Protein quantification was performed using a DCnylon filters followed by hybridization with an oligonucleotide probe as de-
protein assay kit (BioRad). Immunoprecipitation studies to detect ETV6-scribed (Bourgeois et al., 2000), and by sequencing of the PCR products.
NTRK3 were performed on 500 g of total cell lysate (TCL) using 5 l ofThe presence of amplifiable RNA in all samples was confirmed by RT-PCR
-TrkC 14 antibodies (Santa Cruz) and 20 l of Protein A sepharose (Amer-using control primer sets.
sham Pharmacia Biotech). Washed immunoprecipitates were electropho-RT-PCR of ETV6-NTRK3 fusion transcripts in formalin-fixed paraffin-
resed using 10% SDS-polyacrylamide gels, and transferred to Immobilon-Pembedded sections was based on previously described methods (Bourgeois
(Millipore) PVDF prior to immunoblot analysis with 4G10 -phosphotyrosineet al., 2000). Briefly, RNA was isolated from three 30 m paraffin sections
antibodies (Upstate). Proteins were visualized with ECL (Amersham) ac-and used directly in a one-step RT-PCR reaction using the Biosciences
cording to the manufacturer’s protocols. Blots were stripped and reprobedTitanium One Step RT-PCR kit (Clontech). First, the RNA was checked for
with -TrkC14 antibodies to verify the presence of ETV6-NTRK3.integrity using primer pairs for the phosphoglycerate kinase (PGK) gene, as
described previously (Bourgeois et al., 2000). The RNA was then subjected
to RT-PCR using sense TEL971 (5-ACCACATCATGGTCTCTCTGTCTCCC- Tumor growth in nude mice
3) and antisense TRKC1059 (5-CAGTTCTCGCTTCAGCACGATG-3) prim- Two million NIH3T3, Eph4, or Scg6 cells expressing either control MSCV
ers (Bourgeois et al., 2000). PCR conditions were as reported previously, vectors or ETV6-NTRK3 constructs were injected subcutaneously into the
with the assay detecting a 110 bp PCR fragment. Products were confirmed left flanks (MSCV cell lines) or right flanks (ETV6-NTRK3 expressing cell
as ETV6-NTRK3 transcripts by oligonucleotide probing as described above. lines) of five nude male mice per cell line. Tumor injection sites were moni-
tored three times weekly. Calliper measurements were taken when the tu-
mors were large enough to assay. Tumors were excised and weighed afterFluorescence in situ hybridization (FISH)
20 days (for NIH3T3 cells) or 48 days (for Eph4 and Scg6 cell lines) andTwo FISH assays were used to detect the t(12;15) translocation in SBC.
average tumor weights were calculated. Tumor growth over time was esti-Slides containing interphase cell spreads of the index case were prepared
mated using the following equation: tumor length  tumor width  tumorfrom frozen tumor tissue and subjected to dual-color FISH as previously
height  0.5236.described (Knezevich et al., 1998b). Probes used included ETV6 exon
1-containing cosmid 179A6 and ETV6 exon 8-containing cosmid 148B6,
which become separated in cells with the t(12;15) translocation (Knezevich Tumor histology
et al., 1998b). For analysis of chromosome breakpoints in formalin-fixed Sections from excised tumors were fixed in 10% formalin and embedded
paraffin-embedded tumor blocks, 5 m sections were first deparaffinized in paraffin using standard protocols. Sections were cut at 5 m and stained
and dehydrated in 100% ethanol using standard methods. Slides were boiled with hematoxylin and eosin (H/E). Immunohistochemistry (IHC) was per-
in 2xSSC for 30 s, washed, and then pretreated in 1M sodium thiocyanate formed on formalin-fixed paraffin-embedded sections using a three-step
for 30 min. Sections were then digested using 5 mg/ml pepsin in 0.2N HCL streptavidin-biotin peroxidase method, with 3-amino-9-ethylcarbazole as
at 37C for 20 min. This was followed by fixation in formaldehyde, dehydration the chromogen. Antibodies utilized included cytokeratin (Z0622 from Dako;
with ethanol, and denaturation with 70% formamide/2xSSC (pH 7.0) at 90C 1:1000 dilution), epithelial membrane antigen (EMA; ID Laboratories; 1:50),
for 6 min. Dual-color FISH was performed using the 12p13 breakpoint- carcinoembryonic antigen (CEA; Dako; 1:200), NTRK3 (TRKC14 from Santa
spanning YAC, 817_H_1 and the 15q25 breakpoint-spanning YAC, 802_B_4 Cruz; 1:40), and vimentin (Nova Castro; 1:100). Microwave antigen retrieval
(Knezevich et al., 1998b). Probes were labeled with Spectrum Green was performed using standards methods. Photomicrographs were taken
(817_H_1) and 0.2 Spectrum Red (802_B_4) by nick translation following with a Zeiss Axioplan 2 microscope equipped with Northern Eclipse version
standard protocols, and hybridized to denatured slides in a humid chamber 5.0 software.
at 37C overnight. These probes become juxtaposed in cells with the t(12;15)
translocation (Knezevich et al., 1998b). Slides were counterstained with DAPI Acknowledgments
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